The Influence of GINkGo Biloba on the Pharmacokinetics of the UGT Substrate raltEgraviR (GINGER)

Trial Profile

The Influence of GINkGo Biloba on the Pharmacokinetics of the UGT Substrate raltEgraviR (GINGER)

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2012

At a glance

  • Drugs Ginkgo biloba (Primary) ; Raltegravir (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Acronyms GINGER
  • Most Recent Events

    • 15 Oct 2011 Results presented at the 13th European AIDS Conference.
    • 11 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
    • 11 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top